

Peter Nicolas Ruygrok

BSc, MBChB, MD, FRACP, FCSANZ, FESC

Curriculum Vitae

11 June 2008

Director – Mercy Angiography Limited

1999

Reviewer for: EuroIntervention, HRC, European Heart Journal, Internal Med Journal, JACC, AJC

Elected President - Society of Cardiopulmonary Technology (NZ) Incorporated

Elected Chairman Board of Directors – Auckland Heart Institute

Convenor 20 years of Heart Transplantation celebration symposium

2000

Faculty member Asia Pacific Congress of Heart failure – Melbourne

External Assessor – Left Ventricular Assist Device Programme - Royal Perth Hospital

Reviewer for: EuroIntervention, European Heart Journal, Lancet

Faculty member TCT interventional cardiology meeting

Recipient of “Most Challenging Case Award” TCT 2008

CURRENT APPOINTMENTS

Clinical Director and Consultant Cardiologist, Green Lane Cardiovascular Service, Auckland District Health Board – Auckland City Hospital (previously Green Lane Hospital) – with special interests in Interventional Cardiology & Transplant Cardiology

Visiting Interventional Cardiologist - Middlemore Hospital

Visiting Cardiologist Auckland Heart Group & Mercy Hospital

Clinical Associate Professor of Medicine, University of Auckland

FIVE MOST INFLUENTIAL PUBLICATIONS

1. Ruygrok PN, de Jaegere PPT, van Domburg RT, van den Brand MJ, Serruys PW, de Feyter PJ. Clinical outcome 10 years after percutaneous transluminal coronary angioplasty in 856 patients. *J Am Coll Cardiol* 1996; 27:1669-77.
2. Ruygrok PN, Melkert R, Morel M-A, et al. Does six month follow-up angiography influence clinical management and outcome. *J Am Coll Cardiol* 1999;34:1507-11.
3. Ruygrok PN, Webster MWI, de Valk V, van Es GA, Ormiston JA, Morel MA, Serruys PW. Clinical and angiographic factors associated with asymptomatic restenosis after percutaneous coronary intervention. *Circulation* 2001;104:2289-94.
4. West NEJ, Ruygrok PN, Disco CMC, Webster MWI, Lindeboom WK, O'Neill WW, Mercado NF, Serruys PW. Clinical and angiographic predictors of restenosis following stent implantation in diabetic patients. *Circulation* 2004;109:867-873.

5. Keogh A, Richardson M, Ruygrok P, Sprat P, Galbraith A, O'Driscoll G, Macdonald P, Esmore D, Muller D, Faddy S. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary disease at 2 years. A randomized clinical trial. *Circulation* 2004;110:r10-r16.